Pulse Bio AF Trial Enrolls Early But Runway Tightens
Pulse Biosciences enrolled 164 evaluable patients in its atrial fibrillation pivotal trial three months ahead of schedule, moving the nPulse Cardiac Catheter System toward regulatory submission. The c
Pulse Bio AF Trial Fills 3 Months Early, But Raises Loom
NEW YORK, October 20 —
Pulse Biosciences, Inc. (PLSE) enrolled 164 evaluable patients in its atrial fibrillation key trial three months ahead of schedule. The clinical win arrived as the company had already filed two separate equity offerings in a 40-day window from a zero-revenue base.
- AF trial hit 164-patient enrollment target three months early, accelerating path to regulatory submission for the nPulse Cardiac Catheter System.
- Two 424B5 equity offerings in 40 days; $100M cash implies 18-20 months runway at current burn rate.
- COO Liane Rae Teplitsky bought 4,095 shares for ~$200,000 between the two offerings; zero insider sales over the period.
Full-Circle Ablation, Faster Than Rivals
Pulse Biosciences makes devices using nanosecond pulsed field ablation, a nonthermal technique that destroys cardiac tissue without heat. The nPulse Cardiac Catheter System delivers circumferential ablation in a single treatment cycle, sidestepping the multiple sequential lesion lines that competing approaches require. BTIG cited European first-in-human data across 141 patients showing strong procedural success to 12 months, and noted the nanosecond platform operates faster than microsecond-based competitors. Mizuho, Oppenheimer, and Canaccord have all raised targets in recent months, clustering in the $55-$73 range; the $62.33 consensus sits roughly 24% above $47.55, a spread that a DCF calculator can frame but not resolve without the regulatory outcome.
Two Raises Before a Dollar of Revenue
Pulse Biosciences generated essentially no product revenue on a trailing twelve-month basis, carrying a $3.39 billion market capitalization dependent entirely on clinical and regulatory outcomes. Against $61 million in annual operating cash outflow and negative $34 million in free cash flow, the company held $100 million in cash against $10 million in debt, implying roughly 18 to 20 months of runway before the two recent offerings. Between the August 6 and September 15 filings, COO Liane Rae Teplitsky bought 4,095 shares across four open-market transactions at $48.23 to $49.95, spending approximately $200,000 of her own capital. Short interest stands at 15.5% of float, the mirror-image bet.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PLSE | $3.4B | n/a | +144.0% |
| PTGX | $8.7B | n/a | +71.7% |
| AXGN | $2.1B | 48.9x | +97.9% |
| CUE | $117M | n/a | -32.5% |
| KIDS | $575M | n/a | +22.6% |
| VRCA | $59M | n/a | -11.0% |
Enrollment Is Not Approval
Regulatory submission is the next gate, and its timing determines whether current capital is sufficient. With 71.0% insider ownership and 15.4% institutional holdings, the shareholder base is concentrated enough that another dilutive raise would absorb into shallow external float. The nsPFA platform runs wider than one device: the nPulse System treats benign skin lesions, the Vybrance electrode targets soft-tissue surgery, and a surgical clamp addresses open-AF procedures, providing optionality if the catheter timeline slips. The figure that breaks the runway thesis is not the current share price but the regulatory submission date; early enrollment narrows the gap but does not close it. Run the free Pulse Biosciences, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What is the Pulse Bio AF trial status?
Pulse Biosciences enrolled 164 evaluable patients in its atrial fibrillation pivotal trial three months ahead of schedule. Regulatory submission for the nPulse Cardiac Catheter System is the next gate.
How does the nPulse ablation catheter work?
The nPulse Cardiac Catheter System uses nanosecond pulsed field ablation, a nonthermal technique that destroys cardiac tissue without heat. It delivers circumferential ablation in a single treatment cycle, faster than competing microsecond-based approaches.
Does Pulse Biosciences generate revenue?
Pulse Biosciences generated essentially no product revenue on a trailing twelve-month basis. The $3.39 billion market cap depends entirely on clinical and regulatory outcomes.
Why did Pulse Bio raise capital twice in 40 days?
With $61 million in annual operating cash outflow and $100 million in cash, the company has approximately 18 to 20 months of runway. The August 6 and September 15 equity offerings were filed against that timeline.
When will Pulse Bio receive FDA approval?
Regulatory submission is the next gate; its timing determines whether current capital is sufficient. Early enrollment narrows the gap but does not close it; approval remains uncertain.
Pulse Biosciences' atrial fibrillation pivotal trial enrolled 164 evaluable patients and hit its enrollment goal three months ahead of schedule — an acceleration that signals clinical confidence in the nsPFA platform but arrives as the company has already tapped equity markets twice in 40 days from a zero-revenue base.